- Governmental grant for new pilot research project, in line with growth strategy.
- New Mammo 2 product successfully launched at RSNA.
- New product configuration for Ultrasound Point-of-Care.
Q4 FINANCIAL DATA
- Sales of 15.5 MSEK (20.5).
- Operating result of 3.7 MSEK (1.6) and operating margin of 23.7% (7.8%).
- Earnings per share of 0,37 (0,20) SEK.
Please find the report here.
A video presentation by CEO Anita Tollstadius will follow on Friday February 21, at 9.00 CET.
Please follow the link: webbtv.nu/contextvisionq42013